SCHEMBL3940599

SCHEMBL3940599

O=C(O)C1CCC(CNS(=O)(=O)c2cc(OCC(F)(F)F)ccc2OCC(F)(F)F)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
POLB P06746 2/20 0.47
CYP2C9 P11712 5/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CYP1A2 P05177 5/20 0.46
CYP2D6 P10635 4/20 0.46
LMNA P02545 3/20 0.46
CYP3A4 P08684 3/20 0.46
CYP2C19 P33261 3/20 0.46
CNR2 P34972 6/20 0.44
CNR1 P21554 5/20 0.44
KDM4E B2RXH2 1/20 0.43
TSHR P16473 1/20 0.42
CACNA1F O60840 1/20 0.42
KCNA5 P22460 1/20 0.42
SLC6A2 P23975 1/20 0.42
ADRA1A P35348 1/20 0.42
OPRK1 P41145 1/20 0.42
CACNA1D Q01668 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3940595 1.00 ALDH1A1 (0.47) ALDH1A1POLBCYP2C9MEN1KMT2A
SCHEMBL3943115 0.92 ALDH1A1 (0.47) ALDH1A1POLBCYP2C9MEN1KMT2A
SCHEMBL3943111 0.92 ALDH1A1 (0.47) ALDH1A1POLBCYP2C9MEN1KMT2A
SCHEMBL3944492 0.86 CNR2 (0.46) ALDH1A1POLBCYP2C9CYP1A2CYP2D6
SCHEMBL3944489 0.86 CNR2 (0.46) ALDH1A1POLBCYP2C9CYP1A2CYP2D6
SCHEMBL13796479 0.84 CYP1A2 (0.43) ALDH1A1POLBCYP2C9MEN1KMT2A
SCHEMBL13796789 0.75 NPY5R (0.51) ALDH1A1POLBKMT2AHPGD
SCHEMBL13796389 0.75 NPY5R (0.51) ALDH1A1HPGD
SCHEMBL13485842 0.75 KDM4E (0.57) ALDH1A1POLBCYP2C9MEN1KMT2A
SCHEMBL13793590 0.74 NPY5R (0.65) ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544690-B2 MCH receptor antagonists TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-06-09 US disclosed
US-20070037836-A1 Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide TAISHO PHARMACEUTICAL CO., LTD. (JP) 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037836-A1 Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide MCHR1, MCHR2, MC4R ALDH1A1 1616/4885POLB 4305/4885CYP2C9 1317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.